Mumbai: Dabur Pharma has reported a consolidated net profit of Rs98.6 crore for the year ended March 2008, as against Rs19.7 crore in the previous corresponding period.
Consolidated revenues stood at Rs278.30 crore for the fiscal year 2007-08 whereas the same were at Rs326.70 crore in 2006-07.
“The company’s overall sales during 2007-08 were lower than last year on account of the divesture of non-oncology business to Alembic in March 2007. However, on a like to like basis, the oncology business recorded a sales growth of over 11% on a consolidated basis and 5% on a standalone basis,” the firm said in a filing to the Bombay Stock Exchange (BSE).
The year also saw a 30% growth in oncology formulations business.
“It was the first full year of operations as a pure oncology player and the focus has started yielding positive results which is clearly visible in the excellent oncology formulations growth,” Ajay Kumar Vij, CEO, Dabur Pharma said.
In late afternoon trade, shares of the firm were trading at Rs73.05 on the BSE.